Molbio Diagnostics Limited IPO — Subscription & GMP

listedMainboardBOTHNSE: MOLBIOBSE: MOLBIOBSE code: 4729
Grey market premiumat close
+₹122
final quote · 12 Aug 2026 · bidding closed
Implied listing gainat close
+15.12%
implies ₹929 on listing
Subscribed
43.07×
exchange data · 4 hr ago
Min. investment
₹14,526
18 shares × ₹807
Price band
₹768 – ₹807
Lot size
18
Issue size
₹658.39 Cr
Bidding
10 Aug 2026 → 12 Aug 2026
Allotment
13 Aug 2026
Listing
17 Aug 2026

Listing outcome

Official exchange prices
Listed at₹980vs ₹807 issue price
+21.44%listing gain
Grey market prediction vs reality
GMP implied+15.12%
Actually listed+21.44%

GMP was out by 6.3 percentage points in the buyer’s favour — it implied +15.12% and the issue listed +21.44%. Counted in our running GMP accuracy record.

Listing date17 Aug 2026
Day 1 close₹1,042 (+6.30%)
GMP at close of bidding₹122 premium
SourceExchange bhavcopy

Schedule

  1. 10 Aug 2026IPO open date
  2. 12 Aug 2026IPO close date
  3. 13 Aug 2026Allotment date
  4. 14 Aug 2026Funds unblock or debit
  5. 17 Aug 2026Tentative listing date

Fundamentals

The business, its valuation and returns

Molbio Diagnostics Limited operates as an innovative global point-of-care (POC) molecular diagnostics company, providing rapid, decentralized testing solutions for infectious and non-communicable diseases to public health programs, hospitals, and diagnostic laboratories.

Its flagship product is the Truenat platform—a portable, battery-operated real-time PCR system recognized by the WHO and deployed in over 85 countries—complemented by a strategically expanding portfolio in portable radiology, digital pathology, and breast cancer screening. The company leverages a highly profitable recurring revenue model: after the initial sale of a Truenat device, it generates continuous, long-term income from the proprietary disposable test kits, microchips, and reagents required to run every test. This recurring demand is the financial backbone of the business, with consumable test kits contributing nearly 74% of its operating revenue in FY26. By designing its testing chips to work exclusively with its own platforms and operating in a market with high entry barriers requiring years of R&D, Molbio ensures strong customer lock-in and sustainable growth.

RoNW
14.55%
latest reported year · strong above 15%
PAT margin
11.35%
net profit as a share of revenue
Revenue
1,445.69 Cr
PAT ₹164.14 Cr
MetricPre-issuePost-issue
EPS₹14.77
P/E ratio at cap price54.64×

Promoter holding pre/post issue is in the offer document but we do not yet extract it. Left blank rather than estimated.

Read from the company’s offer document filed with SEBI. Figures are the latest reported financial year, as restated in that filing.

Figures are as reported and not independently audited, and are read 7 d ago.

GMP is unofficial. Grey Market Premium is quoted by private dealers outside the exchange mechanism and is not recognised or regulated by SEBI. Figures vary by source, can change within minutes, and frequently diverge from actual listing prices. UpcomingIPO publishes GMP as market information only — this is not investment advice and not a recommendation to apply for any issue.

Grey market premium

Unofficial · not from any exchange
No grey market premium is being quoted for this issue. Unlike subscription, GMP has no official source — when dealers are not quoting it, there is nothing to report.

Subscription status

Live from NSE · fetched 4 hr ago
Overall subscribed
43.07×
exchange data, 4 hr ago
QIB
108.63×
25.26 Cr of 23.25 L shares
NII
35.35×
6.16 Cr of 17.44 L shares
Retail
9.08×
3.69 Cr of 40.69 L shares
CategoryShares offeredShares bid forSubscribed
1Qualified Institutional Buyers(QIBs)23.25 L25.26 Cr108.63×
1(a)Foreign Institutional Investors(FIIs)8.13 Cr
1(b)Domestic Financial Institutions(Banks/ Financial Institutions(FIs)/ Insurance Companies)15.06 Cr
1(c)Mutual funds1.24 L
1(d)Others2.06 Cr
2Non Institutional Investors17.44 L6.16 Cr35.35×
2.1Non Institutional Investors(Bid amount of more than Ten Lakh Rupees)11.63 L4.25 Cr36.52×
2.1(a)Corporates5.29 L
2.1(b)Individuals(Other than RIIs)4.02 Cr
2.2Non Institutional Investors(Bid amount of more than Two Lakh Rupees upto Ten Lakh Rupees)5.81 L1.92 Cr33.01×
3Retail Individual Investors(RIIs)40.69 L3.69 Cr9.08×
3(a)Cut Off3.13 Cr
3(b)Price bids56.15 L
4Employees20,5192.21 L10.76×
4(b)Price Bids48,960
Total81.59 L35.14 Cr43.07×

Source: NSE issue information · BSE public issue

Demand curve

Shares bid at each price point · BSE

₹768₹807 · peak 57.36 Cr shares bid

Anchor investors

From NSE's anchor allocation filing

Anchor investors are institutions allotted shares one working day before public bidding opens, in exchange for a lock-in. Up to 60% of the QIB portion can go to them, which reduces the QIB shares left for everyone else — and their participation is widely read as a confidence signal.

Anchor allocation
34.88 L
shares placed with anchors
Anchor price
₹807
per share
Amount raised
₹281.46 Cr
from anchor investors
Investors
33
largest 3.96%
#Anchor investorShares% of anchorAmount
1HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND1.38 L3.96%₹11.14 Cr
2HDFC VALUE FUND1.08 L3.11%₹8.75 Cr
3HDFC MUTUAL FUND - HDFC INNOVATION FUND1.08 L3.11%₹8.75 Cr
4HDFC MUTUAL FUND - HDFC MNC FUND78,8582.26%₹6.36 Cr
5KOTAK CONTRA FUND1.45 L4.15%₹11.67 Cr
6KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK HEALTHCARE FUND1.45 L4.15%₹11.67 Cr
7KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK CONSUMPTION FUND1.45 L4.14%₹11.67 Cr
8ICICI PRUDENTIAL QUALITY FUND1.86 L5.33%₹15.00 Cr
9ISIF EQUITY LONG-SHORT FUND37,1701.07%₹3.00 Cr
10ICICI PRUDENTIAL EXPORTS AND SERVICES FUND1.49 L4.26%₹12.00 Cr
11NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHARMA FUND RCT-RPF2.48 L7.11%₹20.00 Cr
12NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA INNOVATION FUND1.24 L3.55%₹10.00 Cr
13GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO3.10 L8.88%₹25.00 Cr
14GOLDMAN SACHS ETF TRUST - GOLDMAN SACHS INDIA EQUITY ETF61,9741.78%₹5.00 Cr
15INTERNATIONAL FINANCE CORPORATION*2.48 L7.11%₹20.00 Cr
16BLACKROCK GLOBAL FUNDS - INDIA FUND2.48 L7.11%₹20.00 Cr
17MIRAE ASSET HEALTHCARE FUND MIRAHCFD2.48 L7.11%₹20.00 Cr
18WHITEOAK CAPITAL PHARMA AND HEALTHCARE FUND80,5682.31%₹6.50 Cr
19WHITEOAK CAPITAL AGGRESSIVE HYBRID FUND43,3621.24%₹3.50 Cr
20MOTILAL OSWAL LARGE CAP FUND1.24 L3.55%₹10.00 Cr
21TATA INDIA PHARMA & HEALTHCARE FUND1.24 L3.55%₹10.00 Cr
22EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC - EDELWEISS EQUITY SAVINGS FUND92,9342.66%₹7.50 Cr
23EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC- EDELWEISS RECENTLY LISTED IPO FUND30,9960.89%₹2.50 Cr
24HDFC LIFE INSURANCE COMPANY LIMITED88,5972.54%₹7.15 Cr
25AXIS MAX LIFE INSURANCE LIMITED A/C SUSTAINABLE EQUITY FUND - ULIF02505/10/21SUSTAINEQU10435,1041.01%₹2.83 Cr
26AXIS MAX LIFE INSURANCE LIMITED A/C - ULIF00225/06/04LIFEBALANC104 - BALANCED FUND33,3670.96%₹2.69 Cr
27AXIS MAX LIFE INSURANCE LIMITED PENSION MAXIMISER FUND (ULIF01715/02/13PENSMAXIMI104)11,4010.33%₹0.92 Cr
28AXIS MAX LIFE INSURANCE LIMITED A/C UHG2S - INDIA CONSUMPTION OPPORTUNITIES FUND2,6250.08%₹0.21 Cr
29AXIS MAX LIFE INSURANCE LIMITED A/C UMFPH - HIGH GROWTH PENSION FUND2,6250.08%₹0.21 Cr
30AXIS MAX LIFE INSURANCE LIMITED A/C - ULGF00217/04/06GRATBALANC104 -GROUP GRATUITY BALANCED FUND1,7500.05%₹0.14 Cr
31AXIS MAX LIFE INSURANCE LIMITED PENSION PRESERVER FUND(ULIF01815/02/13PENSPRESER104)8620.02%₹0.07 Cr
32AXIS MAX LIFE INSURANCE LIMITED A/C - ULIF00625/11/05PENSBALANC104 - PENSION BALANCED FUND8620.02%₹0.07 Cr
33BAJAJ LIFE INSURANCE LIMITED88,5962.54%₹7.15 Cr

Read from NSE's anchor allocation report · 2 d ago. Published only because the 33 rows reconcile exactly against the 34.88 L shares the filing itself declares.

Equity split

Fresh equity vs offer for sale
₹200.00 Crto the company
Fresh equitynew capital, into the company's books
₹200.00 Cr 21.3%
Offer for saleto selling shareholders — the company receives nothing
₹739.70 Cr 78.7%
Total issue size
₹939.70 Cr

Read from the issue size stated in NSE's filing.

Objects of the issue

Where the fresh issue proceeds go

These add up to ₹200.00 Cr, the whole of the fresh issue. Only the fresh issue has objects — money raised in an offer for sale goes to the selling shareholders and never reaches the company. Compiled from the offer document by Zerodha; the prospectus is the authoritative version.

News about this IPO

All IPO news →

Allotment status

Basis of allotment 13 Aug 2026

You will need your PAN, application number or DP/client ID. These links go to the registrar and exchanges directly — UpcomingIPO never asks for those details.

Issue details

Price band
₹768 – ₹807
Lot size
18 shares
Min. bid quantity
18
Face value
₹1.00
Tick size
₹1.00
Shares offered
81.59 L
Issue size
₹658.39 Cr
Max bid · QIB
81.38 L
Max bid · NII
58.13 L
Employee discount
Employee Discount of Rs 76 to Eligible Employees

Timeline & process

Bidding opens
10 Aug 2026
Bidding closes
12 Aug 2026
Bidding hours
10.00 am to 5.00 pm
UPI mandate cutoff
12-August-2026 (Upto 5.00 pm)
Allotment
13 Aug 2026
Listing
17 Aug 2026

Intermediaries

Registrar
KFin Technologies Limited
Sponsor bank
AXIS BANK
Lead managers
Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited), Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited

Documents

Price band notice
PDF
Prospectus
View